Given that KRAS mutant CRC patients have been shown to be heterogeneous (Budinska et al., 2013; Sadanandam et al., 2013) and given the ability of the GEMM Kras signature to distinguish patients with poor prognosis, we sought to determine whether this signature could further delineate clinical features, specifically in a KRAS mutant patient population. Here, KRAS is linked to colorectal carcinoma.